JP2021522824A - 間葉系間質細胞エキソソーム処置単球およびそれらの使用 - Google Patents

間葉系間質細胞エキソソーム処置単球およびそれらの使用 Download PDF

Info

Publication number
JP2021522824A
JP2021522824A JP2020563539A JP2020563539A JP2021522824A JP 2021522824 A JP2021522824 A JP 2021522824A JP 2020563539 A JP2020563539 A JP 2020563539A JP 2020563539 A JP2020563539 A JP 2020563539A JP 2021522824 A JP2021522824 A JP 2021522824A
Authority
JP
Japan
Prior art keywords
monocytes
isolated
msc
treated
mex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020563539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522824A5 (https=
JPWO2019217646A5 (https=
Inventor
コウレンバナス，ステラ
ミツィアリス，エス．アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2021522824A publication Critical patent/JP2021522824A/ja
Publication of JP2021522824A5 publication Critical patent/JP2021522824A5/ja
Publication of JPWO2019217646A5 publication Critical patent/JPWO2019217646A5/ja
Priority to JP2024058604A priority Critical patent/JP2024163978A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020563539A 2018-05-09 2019-05-09 間葉系間質細胞エキソソーム処置単球およびそれらの使用 Pending JP2021522824A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024058604A JP2024163978A (ja) 2018-05-09 2024-04-01 間葉系間質細胞エキソソーム処置単球およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669324P 2018-05-09 2018-05-09
US62/669,324 2018-05-09
PCT/US2019/031467 WO2019217646A1 (en) 2018-05-09 2019-05-09 Mesenchymal stromal cell exosome -treated monocytes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024058604A Division JP2024163978A (ja) 2018-05-09 2024-04-01 間葉系間質細胞エキソソーム処置単球およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2021522824A true JP2021522824A (ja) 2021-09-02
JP2021522824A5 JP2021522824A5 (https=) 2022-05-12
JPWO2019217646A5 JPWO2019217646A5 (https=) 2022-05-12

Family

ID=68467835

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563539A Pending JP2021522824A (ja) 2018-05-09 2019-05-09 間葉系間質細胞エキソソーム処置単球およびそれらの使用
JP2024058604A Pending JP2024163978A (ja) 2018-05-09 2024-04-01 間葉系間質細胞エキソソーム処置単球およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024058604A Pending JP2024163978A (ja) 2018-05-09 2024-04-01 間葉系間質細胞エキソソーム処置単球およびそれらの使用

Country Status (6)

Country Link
US (1) US20210213056A1 (https=)
EP (1) EP3790560A4 (https=)
JP (2) JP2021522824A (https=)
CN (1) CN112469423A (https=)
CA (1) CA3099042A1 (https=)
WO (1) WO2019217646A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525233A (ja) * 2022-09-02 2025-08-01 財團法人醫藥工業技術發展中心 骨髄線維症の緩和のための間葉系幹細胞を含む組成物の使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2949083C (en) 2014-05-18 2023-10-10 Children's Medical Center Corporation Methods and compositions relating to exosomes
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
CN112334190B (zh) 2018-04-30 2024-09-20 儿童医学中心公司 间充质基质细胞外排体及其用途
WO2021145395A1 (ja) * 2020-01-15 2021-07-22 富士フイルム和光純薬株式会社 抗線維化剤、及び抗線維化作用を有する細胞外小胞の製造方法
WO2021145396A1 (ja) 2020-01-15 2021-07-22 富士フイルム和光純薬株式会社 血管新生剤、及び血管新生作用を有する細胞外小胞の製造方法
US20230248773A1 (en) 2020-07-09 2023-08-10 Exo Biologics Sa Extracellular Vesicles and Compositions Thereof
US20220127579A1 (en) * 2020-10-22 2022-04-28 Wisconsin Alumni Research Foundation Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury
CN116999463A (zh) * 2022-04-27 2023-11-07 中山大学附属第三医院 一种间充质干细胞来源外泌体在制备治疗间质性膀胱炎药物中的应用
CN115475250B (zh) * 2022-05-26 2024-03-26 南京鼓楼医院 一种靶向肝星状细胞并抑制其激活的载药外泌体及其制备和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183825A1 (en) * 2017-03-31 2018-10-04 Wisconsin Alumni Research Foundation Generation of therapeutic cells using extracellular components of target organs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944361A1 (en) * 2007-01-11 2008-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for expanding monocytes
US20130273011A1 (en) * 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
US10166254B2 (en) * 2014-09-19 2019-01-01 Wisconsin Alumni Research Foundation Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
US10876753B2 (en) * 2018-02-12 2020-12-29 Watsco Ventures Llc Integrated sensor and service port for HVAC equipment or HVAC system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183825A1 (en) * 2017-03-31 2018-10-04 Wisconsin Alumni Research Foundation Generation of therapeutic cells using extracellular components of target organs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 192, no. 3, JPN6023011846, 2015, pages 324 - 336, ISSN: 0005423165 *
STEM CELLS, vol. 35, JPN6023011845, 2017, pages 316 - 324, ISSN: 0005423166 *
WORLD J. GASTROENTEROL., vol. 18, JPN6023011844, 2012, pages 1048 - 1058, ISSN: 0005423167 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525233A (ja) * 2022-09-02 2025-08-01 財團法人醫藥工業技術發展中心 骨髄線維症の緩和のための間葉系幹細胞を含む組成物の使用

Also Published As

Publication number Publication date
CA3099042A1 (en) 2019-11-14
JP2024163978A (ja) 2024-11-26
WO2019217646A1 (en) 2019-11-14
EP3790560A4 (en) 2022-03-30
EP3790560A1 (en) 2021-03-17
WO2019217646A8 (en) 2020-01-23
US20210213056A1 (en) 2021-07-15
CN112469423A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
JP2021522824A (ja) 間葉系間質細胞エキソソーム処置単球およびそれらの使用
US12257270B2 (en) Treatment of immune disorders
Kerkis et al. Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: local or systemic?
JP6773563B2 (ja) エキソソームに関連する方法および組成物
Strakova et al. Multipotent properties of myofibroblast cells derived from human placenta
CA3072562A1 (en) Purified mesenchymal stem cell exosomes and uses thereof
KR102405663B1 (ko) 개선된 줄기 세포 조성물
Zhang et al. RETRACTED ARTICLE: Therapeutic potential of non-adherent BM-derived mesenchymal stem cells in tissue regeneration
Wu et al. Cardiac potential of stem cells from whole human umbilical cord tissue
Guo et al. Mesenchymal stem cells reprogram host macrophages to attenuate obliterative bronchiolitis in murine orthotopic tracheal transplantation
JP5809068B2 (ja) 免疫抑制−関連疾患の治療
US20160287642A1 (en) Methods of treating or preventing a lung disorder
Bentley et al. Ovalbumin sensitization and challenge increases the number of lung cells possessing a mesenchymal stromal cell phenotype
Muñoz et al. Cell tracking, survival, and differentiation capacity of adipose‐derived stem cells after engraftment in rat tissue
Li et al. Therapeutic potential of urine-derived stem cells in renal regeneration following acute kidney injury: A comparative analysis with mesenchymal stem cells
Mao et al. Ex vivo expanded human cord blood-derived hematopoietic progenitor cells induce lung growth and alveolarization in injured newborn lungs
US9044431B2 (en) Methods of treating stroke using stem cell-like menstrual blood cells
KR20250130613A (ko) 세포 조성물을 이용한 염증 치료 방법
Ren et al. Effect of umbilical cord mesenchymal stem cell transplantation under LIFPUS pretreatment on thyroid function in EAT rats
US20100310530A1 (en) Cell Therapy for Brain Tissue Damage
WO2017199976A1 (ja) 多能性幹細胞による周産期脳障害の改善及び治療
JP7003283B2 (ja) 末梢血から間葉系幹細胞集団を製造する方法及びその使用
JP7165352B2 (ja) 多能性幹細胞による慢性肺疾患の改善及び治療
US20140286910A1 (en) Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
WO2011159981A2 (en) Lung regeneration using cord blood-derived hematopoietic stem cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240605

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240927